NDC 72974-120

Orgovyx

Relugolix

Orgovyx is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Myovant Sciences, Inc.. The primary component is Relugolix.

Product ID72974-120_05bc4a55-f7d7-4349-a7f6-86185c334d56
NDC72974-120
Product TypeHuman Prescription Drug
Proprietary NameOrgovyx
Generic NameRelugolix
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2020-12-18
Marketing CategoryNDA / NDA
Application NumberNDA214621
Labeler NameMyovant Sciences, Inc.
Substance NameRELUGOLIX
Active Ingredient Strength120 mg/1
Pharm ClassesBreast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 72974-120-01

30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72974-120-01)
Marketing Start Date2020-12-18
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Orgovyx]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ORGOVYX
ORGOVYX
90648307 not registered Live/Pending
Myovant Sciences GmbH
2021-04-15
ORGOVYX
ORGOVYX
90648278 not registered Live/Pending
Myovant Sciences GmbH
2021-04-15
ORGOVYX
ORGOVYX
90648244 not registered Live/Pending
Myovant Sciences GmbH
2021-04-15
ORGOVYX
ORGOVYX
90132142 not registered Live/Pending
Myovant Sciences GmbH
2020-08-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.